Last reviewed · How we verify

Retagliptin, Henagliflozein, metformin XR

Jiangsu HengRui Medicine Co., Ltd. · Phase 3 active Small molecule

Retagliptin, Henagliflozein, metformin XR is a DPP-4 inhibitor, GLP-1 receptor agonist, biguanide Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 3 development for Treatment of type 2 diabetes.

Retagliptin, Henagliflozein, and metformin XR work together to lower blood sugar levels by enhancing insulin secretion and suppressing glucagon release, and also by decreasing glucose reabsorption in the kidneys.

Retagliptin, Henagliflozein, and metformin XR work together to lower blood sugar levels by enhancing insulin secretion and suppressing glucagon release, and also by decreasing glucose reabsorption in the kidneys. Used for Treatment of type 2 diabetes.

At a glance

Generic nameRetagliptin, Henagliflozein, metformin XR
SponsorJiangsu HengRui Medicine Co., Ltd.
Drug classDPP-4 inhibitor, GLP-1 receptor agonist, biguanide
TargetDPP-4, GLP-1R
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Retagliptin is a DPP-4 inhibitor, Henagliflozein is a GLP-1 receptor agonist, and metformin XR is a biguanide. By combining these mechanisms, the drug aims to improve glycemic control in patients with type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Retagliptin, Henagliflozein, metformin XR

What is Retagliptin, Henagliflozein, metformin XR?

Retagliptin, Henagliflozein, metformin XR is a DPP-4 inhibitor, GLP-1 receptor agonist, biguanide drug developed by Jiangsu HengRui Medicine Co., Ltd., indicated for Treatment of type 2 diabetes.

How does Retagliptin, Henagliflozein, metformin XR work?

Retagliptin, Henagliflozein, and metformin XR work together to lower blood sugar levels by enhancing insulin secretion and suppressing glucagon release, and also by decreasing glucose reabsorption in the kidneys.

What is Retagliptin, Henagliflozein, metformin XR used for?

Retagliptin, Henagliflozein, metformin XR is indicated for Treatment of type 2 diabetes.

Who makes Retagliptin, Henagliflozein, metformin XR?

Retagliptin, Henagliflozein, metformin XR is developed by Jiangsu HengRui Medicine Co., Ltd. (see full Jiangsu HengRui Medicine Co., Ltd. pipeline at /company/jiangsu-hengrui-medicine-co-ltd).

What drug class is Retagliptin, Henagliflozein, metformin XR in?

Retagliptin, Henagliflozein, metformin XR belongs to the DPP-4 inhibitor, GLP-1 receptor agonist, biguanide class. See all DPP-4 inhibitor, GLP-1 receptor agonist, biguanide drugs at /class/dpp-4-inhibitor-glp-1-receptor-agonist-biguanide.

What development phase is Retagliptin, Henagliflozein, metformin XR in?

Retagliptin, Henagliflozein, metformin XR is in Phase 3.

What are the side effects of Retagliptin, Henagliflozein, metformin XR?

Common side effects of Retagliptin, Henagliflozein, metformin XR include Nausea, Diarrhea, Vomiting, Abdominal pain, Headache.

What does Retagliptin, Henagliflozein, metformin XR target?

Retagliptin, Henagliflozein, metformin XR targets DPP-4, GLP-1R and is a DPP-4 inhibitor, GLP-1 receptor agonist, biguanide.

Related